Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: A Systematic Review

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Pielen, Amelie ^a,b   Feltgen, Nicolas ^c   Isserstedt, Christin ^c   Callizo, Josep ^c   Junker, Bernd ^a,b   Schmucker, Christine ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE;

ARTICLE; BLEEDING; BRANCH RETINAL ARTERY OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; ENDOPHTHALMITIS; HEART INFARCTION; HUMAN; INFECTION; INTRAOCULAR PRESSURE; META ANALYSIS; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA MACULA EDEMA; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TREATMENT DURATION; VISUAL ACUITY;

HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; PATIENT SAFETY; RETINAL VEIN OCCLUSION; RISK ASSESSMENT;

EID: 84886406141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078538     Document Type: Article

References (42)

1. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group (1997). Arch Ophthalmol 115: 486-491. doi:10.1001/archopht.1997.01100150488006. PubMed: 9109757.
2. the Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98: 271-282. PubMed: 6383055.
3. Jonas JB, Kreissig I, Degenring RF, (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240: 782-783. doi:10.1007/s00417-002-0529-0. PubMed: 12271378.
4. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, et al.; (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6 Arch Ophthalmol 127: 1115-1128 doi:10.1001/archophthalmol.2009.233.
5. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, et al.; (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5 Arch Ophthalmol 127: 1101-1114 doi:10.1001/archophthalmol.2009.234.
6. Jain N, Stinnett SS, Jaffe GJ, (2012) Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 119: 132-137. doi:10.1016/j.ophtha.2011.06.019. PubMed: 21924503.
7. Kube T, Sutter M, Trittler R, Feltgen N, Hansen LL, et al. (2006) Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 244: 1385-1390. doi:10.1007/s00417-006-0326-2. PubMed: 16715253.
8. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, et al. (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118: 2453-2460. doi:10.1016/j.ophtha.2011.05.014. PubMed: 21764136.
9. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, et al. (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 1171134-1146.e3 doi:10.1016/j.ophtha.2010.03.032. PubMed: 20417567.
10. Ng EWM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132. doi:10.1038/nrd1955. PubMed: 16518379.
11. Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, et al. (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 1131508:: e1-25. doi:10.1016/j.ophtha.2006.02.064. PubMed: 16828500.
12. Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, et al. (2009) Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127: 374-380. doi:10.1001/archophthalmol.2009.14. PubMed: 19365011.
13. Wroblewski JJ, Wells JA 3rd, Gonzales CR, (2010) Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol 149: 147-154. doi:10.1016/j.ajo.2009.08.005. PubMed: 19875087.
14. Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398. doi:10.1016/j.ophtha.2012.03.053. PubMed: 22555112.
15. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119: 1399-1411. doi:10.1016/j.ophtha.2012.04.015. PubMed: 22578446.
16. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, et al. (2011) Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249: 183-192. doi:10.1007/s00417-010-1470-2. PubMed: 21337042.
17. Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N, (2010) Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol 20: 180-185. PubMed: 19927266.
18. Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, et al. (2009) Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis. Retina (Phila, Pa) 29: 1242-1248. doi:10.1097/IAE.0b013e3181aa8e20. PubMed: 19672216.
19. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U_S_A 99: 11393-11398. doi:10.1073/pnas.172398299. PubMed: 12177445.
20. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, et al. (2013) Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. Am J Ophthalmol 155429-437.e7 doi:10.1016/j.ajo.2012.09.026. PubMed: 23218699.
21. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, et al. (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171-185. doi:10.1007/s10456-011-9249-6. PubMed: 22302382.
22. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, et al. (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118: 2041-2049. doi:10.1016/j.ophtha.2011.02.038. PubMed: 21715011.
23. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, et al. (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118: 1594-1602. doi:10.1016/j.ophtha.2011.02.022. PubMed: 21684606.
24. Centre for Reviews and Dissemination (n.d.) Systematic reviews of adverse effects. Systematic Reviews- CRD's guidance for undertaking reviews in health care. York. pp. 177-198.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6: e1000097. doi:10.1371/journal.pmed.1000097.
26. Epstein DL, Algvere PV, Von Wendt G, Seregard S, Kvanta A, (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119: 2587-2591. doi:10.1016/j.ophtha.2012.06.037. PubMed: 22902212.
27. Parodi MB, Iacono P, Ravalico G, (2008) Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol 92: 1046-1050. doi:10.1136/bjo.2007.128025. PubMed: 18556425.
28. Russo V, Barone A, Conte E, Prascina F, Stella A, et al. (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Phila, Pa) 29: 511-515. doi:10.1097/IAE.0b013e318195ca65. PubMed: 19174717.
29. Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C, (2012) Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 22: 607-614. doi:10.5301/ejo.5000085. PubMed: 22101497.
30. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, et al. (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119: 802-809. doi:10.1016/j.ophtha.2011.12.005. PubMed: 22301066.
31. Epstein DLJ, Algvere PV, Von Wendt G, Seregard S, Kvanta A, (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119: 1184-1189. doi:10.1016/j.ophtha.2012.01.022. PubMed: 22424833.
32. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, et al. (2011) SCORE Study report 11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology 118: 1364-1372. doi:10.1016/j.ophtha.2010.11.020. PubMed: 21440942.
33. Holz FG, Roider J, Ogura Y, Korobelnik J-F, Simader C, et al. (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol, 97: 278-84. doi:10.1136/bjophthalmol-2012-301504. PubMed: 23298885.
34. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, et al. (2009) SCORE Study report 3: study design and baseline characteristics. Ophthalmology 1161770-1777.e1 doi:10.1016/j.ophtha.2009.03.022. PubMed: 19619896.
35. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, et al. (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLOS ONE 7: e42701. doi:10.1371/journal.pone.0042701. PubMed: 22880086.
36. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, et al. (2012) Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 119: 1024-1032. doi:10.1016/j.ophtha.2012.01.042. PubMed: 22440275.
37. Cugati S, Wang JJ, Rochtchina E, Mitchell P, (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124: 726-732. doi:10.1001/archopht.124.5.726. PubMed: 16682596.
38. Klein R, Peto T, Bird A, Vannewkirk MR, (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137: 486-495. doi:10.1016/j.ajo.2003.11.069. PubMed: 15013873.
39. Mitry D, Bunce C, Charteris D, (2013) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 1CD009510: CD009510. Retrieved onpublished at whilst December year 1111 from doi:10.1002/14651858.CD009510.pub2. PubMed: 23440840.
40. Braithwaite T, Nanji AA, Greenberg PB, (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev CD: pp. 007325. Retrieved onpublished at whilst December year 1111 from doi:10.1002/14651858.CD007325.pub2 PubMed: 20927757.
41. Smiddy WE, (2011) Economic considerations of macular edema therapies. Ophthalmology 118: 1827-1833. doi:10.1016/j.ophtha.2010.12.034. PubMed: 21507488.
42. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, et al. (2010) Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 21: 218-226. doi:10.1097/ICU.0b013e3283386783. PubMed: 20393293.